Sp453

BASIL I. HIRSCHOWITZ MD ENDOWED LECTURE

Date
May 19, 2024

Presenter

Speaker Image for Marla Dubinsky
Icahn School of Medicine, Mount Sinai

Tracks

Related Products

Thumbnail for EARLY INTESTINAL ULTRASOUND RESPONSE TO BIOLOGIC AND SMALL MOLECULE THERAPY PREDICTS ENDOSCOPIC OUTCOMES IN CHILDREN WITH ULCERATIVE COLITIS
EARLY INTESTINAL ULTRASOUND RESPONSE TO BIOLOGIC AND SMALL MOLECULE THERAPY PREDICTS ENDOSCOPIC OUTCOMES IN CHILDREN WITH ULCERATIVE COLITIS
INTRODUCTION: Stride-II recommends early biomarker targets for treatment optimization to achieve treat-to-target (T2T) endoscopic remission (ER) in ulcerative colitis (UC). Predictive capabilities of intestinal ultrasound (IUS) for T2T ER remains unknown…
Thumbnail for RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…
Thumbnail for Farron and Martin Brotman, MD, Lecture - Key Challenges in IBD: Strategies and Solutions from the Experts
Thumbnail for CHANGES IN THERAPY ARE NOT ASSOCIATED WITH INCREASED REMISSION IN PATIENTS WITH CROHN’S DISEASE OF THE POUCH
CHANGES IN THERAPY ARE NOT ASSOCIATED WITH INCREASED REMISSION IN PATIENTS WITH CROHN’S DISEASE OF THE POUCH
BACKGROUND: Prevention of postoperative recurrence (POR) in Crohn’s disease (CD) after ileo-colonic (IC) resection is still a highly debated topic. Prophylactic immunosuppression after surgery is currently recommended in presence of at least one clinical risk factor (RF)…